Positive News SentimentPositive NewsNYSE:OGN Organon & Co. (OGN) Stock Price, News & Analysis $9.42 +0.14 (+1.51%) Closing price 08/22/2025 03:59 PM EasternExtended Trading$9.44 +0.02 (+0.16%) As of 08/22/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Organon & Co. Stock (NYSE:OGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Organon & Co. alerts:Sign Up Key Stats Today's Range$9.33▼$9.6450-Day Range$8.43▼$10.2052-Week Range$8.01▼$23.10Volume3.55 million shsAverage Volume4.78 million shsMarket Capitalization$2.45 billionP/E Ratio3.50Dividend Yield0.85%Price Target$18.00Consensus RatingModerate Buy Company Overview Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. Read More Organon & Co. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreOGN MarketRank™: Organon & Co. scored higher than 95% of companies evaluated by MarketBeat, and ranked 59th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingOrganon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageOrganon & Co. has received no research coverage in the past 90 days.Read more about Organon & Co.'s stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth1.63% Earnings GrowthEarnings for Organon & Co. are expected to grow by 1.63% in the coming year, from $3.68 to $3.74 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organon & Co. is 3.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.43.Price to Earnings Ratio vs. SectorThe P/E ratio of Organon & Co. is 3.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.22.Price to Earnings Growth RatioOrganon & Co. has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioOrganon & Co. has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Organon & Co.'s valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.79% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently increased by 2.11%, indicating that investor sentiment is decreasing. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldOrganon & Co. has a dividend yield of 0.85%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOrganon & Co. does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Organon & Co. is 2.97%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Organon & Co. will have a dividend payout ratio of 2.14% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.Read more about Organon & Co.'s dividend. Sustainability and ESG3.7 / 5Environmental Score-2.37 Percentage of Shares Shorted5.79% of the float of Organon & Co. has been sold short.Short Interest Ratio / Days to CoverOrganon & Co. has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organon & Co. has recently increased by 2.11%, indicating that investor sentiment is decreasing. News and Social Media3.6 / 5News Sentiment1.56 News SentimentOrganon & Co. has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Organon & Co. this week, compared to 33 articles on an average week.Search Interest13 people have searched for OGN on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.MarketBeat Follows3 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Organon & Co. insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Organon & Co. is held by insiders.Percentage Held by Institutions77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Organon & Co.'s insider trading history. Receive OGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter. Email Address OGN Stock News HeadlinesThere May Be Some Bright Spots In Organon's (NYSE:OGN) EarningsAugust 15, 2025 | finance.yahoo.comNYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders FoundationAugust 13, 2025 | prnewswire.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).August 23 at 2:00 AM | Weiss Ratings (Ad)Organon: Valuation Discount Offset By Structural HeadwindsAugust 12, 2025 | seekingalpha.comRead This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 DividendAugust 11, 2025 | finance.yahoo.comOrganon & Co. (OGN) Reports Q2 2025 ResultsAugust 7, 2025 | insidermonkey.comOrganon & Co. Earnings Call: Resilience Amid ChallengesAugust 7, 2025 | theglobeandmail.comOrganon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This YearAugust 7, 2025 | finance.yahoo.comSee More Headlines OGN Stock Analysis - Frequently Asked Questions How have OGN shares performed this year? Organon & Co.'s stock was trading at $14.92 at the beginning of the year. Since then, OGN shares have decreased by 36.9% and is now trading at $9.42. How were Organon & Co.'s earnings last quarter? Organon & Co. (NYSE:OGN) released its quarterly earnings data on Tuesday, August, 5th. The company reported $1.00 EPS for the quarter, topping analysts' consensus estimates of $0.94 by $0.06. The company's quarterly revenue was down .8% on a year-over-year basis. Read the conference call transcript. Who are Organon & Co.'s major shareholders? Organon & Co.'s top institutional shareholders include State Street Corp (3.66%), LSV Asset Management (3.07%), Nordea Investment Management AB (1.89%) and Geode Capital Management LLC (1.69%). Insiders that own company stock include Kevin Ali, Matthew M Walsh, Kirke Weaver and Daniel Karp. View institutional ownership trends. How do I buy shares of Organon & Co.? Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Organon & Co. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Organon & Co. investors own include Chevron (CVX), Bristol Myers Squibb (BMY), McKesson (MCK), Comcast (CMCSA), Charles Schwab (SCHW), Edwards Lifesciences (EW) and Yum! Brands (YUM). Company Calendar Record date for 6/12 Dividend5/12/2025Ex-Dividend for 6/12 Dividend5/12/2025Dividend Payable6/12/2025Last Earnings8/05/2025Record date for 9/11 Dividend8/15/2025Ex-Dividend for 9/11 Dividend8/15/2025Today8/23/2025Dividend Payable9/11/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Medical Services Sub-IndustryPharmaceutical Products Current SymbolNYSE:OGN CIK1821825 Webwww.organon.com Phone551-430-6900FaxN/AEmployees4,000Year FoundedN/APrice Target and Rating Average Price Target for Organon & Co.$18.00 High Price Target$24.00 Low Price Target$10.00 Potential Upside/Downside+91.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$2.69 Trailing P/E Ratio3.50 Forward P/E Ratio2.56 P/E Growth0.97Net Income$864 million Net Margins11.15% Pretax Margin10.60% Return on Equity163.88% Return on Assets6.99% Debt Debt-to-Equity Ratio11.98 Current Ratio1.65 Quick Ratio1.13 Sales & Book Value Annual Sales$6.40 billion Price / Sales0.38 Cash Flow$5.01 per share Price / Cash Flow1.88 Book Value$2.82 per share Price / Book3.34Miscellaneous Outstanding Shares259,970,000Free Float254,871,000Market Cap$2.45 billion OptionableNot Optionable Beta0.60 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NYSE:OGN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organon & Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organon & Co. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.